ProKidney FY2025 revenue rises more than 10x to USD 0.89 million as net loss before noncontrolling interest narrows 7.18% to USD 151.61 million

Reuters03-19 04:00
ProKidney FY2025 revenue rises more than 10x to USD 0.89 million as net loss before noncontrolling interest narrows 7.18% to USD 151.61 million

ProKidney published a full-year earnings press release reporting FY 2025 revenue of USD 0.89 million. FY 2025 R&D expense fell 10.6% to USD 114.12 million, driven mainly by lower clinical study costs from trials that were completed or terminated. FY 2025 G&A expense declined 7.7% to USD 51.78 million, mainly due to lower impairment charges and equity-based compensation, partly offset by higher professional fees tied to domestication of foreign subsidiaries to the U.S. and other initiatives. FY 2025 net loss before noncontrolling interest narrowed 7.2% to USD 151.61 million. ProKidney ended FY 2025 with USD 270 million in cash, cash equivalents and marketable securities and said this should fund operations into mid-2027, while it targets completing enrollment for the Phase 3 PROACT 1 accelerated approval efficacy analysis in mid-2026 and reporting topline eGFR slope results in Q2 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prokidney Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603181600PRIMZONEFULLFEED9674776) on March 18, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment